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Purpose: The investigation of anti-inflammatory and immunosuppressive functions of
Kynurenic acid (KYNA) is now in focus. There is also substantial evidence that TSG-6 has
an anti-inflammatory activity. Therefore, in the present study, we compared the effects of
newly synthetized KYNA analogs on the TNF-α production in U-937 monocytic cells in
correlation with the effects on the TSG-6 expression.
Methods: TNF-α production was measured by ELISA, the TSG-6 expression was
determined by RTqPCR method. As cytokine inducers Staphylococcus aureus and
Chlamydia pneumoniae were used.
Results: KYNA and KYNA analogs attenuated TNF-α production and increased TSG-6
mRNA expression in U-937 cells stimulated by heat inactivated Staphylococcus aureus.
In contrast, KYNA and some of the KYNA analogs increased the TNF-α production of
C. pneumoniae infected U-937 cells; however, the newly synthetized analogs (SZR104,
SZR 105, and SZR 109) exerted significant inhibitory effects on the TNF-α synthesis. The
inhibitory and stimulatory effects correlated inversely with the TSG-6 expression.
Conclusions: TSG-6 expression following activation with bacterial components could
participate in the suppression of inflammatory cytokines, such as TNF-α, We suppose
that the elevation of the TSG-6 expression by KYNA and especially by new KYNA
analogs might be one of the mechanisms that are responsible for their suppressive effect
on TNF-α production as a feedback mechanism. KYNA and KYNA analogs have an
important role in influencing TSG-6 expression, and there is a possible benefit of targeting
TSG-6 expression by kynurenines in inflammatory conditions following infections.
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INTRODUCTION
There is an increasing interest in the role of kynurenines in
the immune function. The kynurenine pathway is a regulator of
both innate and adaptive immune responses, and the tryptophan
metabolism kynurenine and production reflect a crucial interface
between the immune and nervous systems (1, 2). Kynurenic
acid (KYNA) is one of the products of the kynurenine pathway
of tryptophan metabolism (3–5). KYNA as an antagonist of
ionotropic glutamate receptors N-methyl-D-aspartate (NMDA)
and the α7 nicotinic acetylcholine receptor (α7nAchR) exert
neuroprotective effects (2, 4–10). KYNA acts both as a blocker
of the glycine co-agonistic site of the NMDA receptor and as
a non-competitive inhibitor of the α7 nicotinic acetylcholine
receptor (11). The investigation of anti-inflammatory and
immunosuppressive functions of KYNA is now in focus. It
has been proved that these immunomodulatory properties
are based on the signaling by G-protein-coupled receptor
35 (GP35) and aryl hydrocarbon receptor (AHR)-mediated
pathways ys (2, 12–14).
Several studies have revealed that KYNA can attenuate
inflammation induced by different stimuli (2, 15, 16). Previously,
we demonstrated that KYNA and a KYNA analog reduced the
TNF-α secretion from human mononuclear cells (17). In the
present study, we compared the effects of newly synthetized
KYNA analogs on the α TNF-α production in U-937 monocytic
cell line. We focused on the potential correlation between the
effects on the TSG-6 (TNFα- stimulated gene 6) expression and
the influence, i.e., the suppression, of TNF-α production by
different KYNA analogs.
Tumor necrosis factor -stimulated gene-6 (TSG-6) product
is an 35-kDa hyaluronan(HA)-binding protein (18, 19)
that is secreted by a wide range of cell types in response
to inflammatory mediators. TSG-6 expression has been
shown to be induced in fibroblasts, chondrocytes, monocytes,
mesenchymal stem cells, vascular smooth muscle cells upon
stimulation by proinflammatory signals (20). Moreover, TSG-6
is expressed by astrocytes in the brain (21). A substantial
number of studies have shown that TSG-6 has anti-inflammatory
activity (18, 20, 22–27).
TSG-6 has been reported to inhibit the association of TLR4
with MyD88, thereby suppressing NF-κB activation (26). TSG-6
has also prevented the expression of proinflammatory proteins
(iNOS, IL-6, TNFα, IL-1β). TSG-6 functions by converting
macrophages from a proinflammatory to an anti-inflammatory
phenotype by suppression of TLR4/NF-κB signaling and STAT1
and STAT3 activation (26).The inhibition of the TLR2 pathway
has also been reported (28).
Therefore, the aim of the present study is to evaluate a
possible connection between the capacity of KYNA and KYNA
analogs on the TSG-6 expression and the inhibition of TNF-α
production first of all in U-937 monocytic cells. Our hypothesis
was that activation of TSG-6 expression might be at least
partially responsible for the TNF-α inhibitory effect of KYNA.
TNF-α induction in U-937 cells was performed with heat killed
Staphylococcus aureus, and the effects were compared with
Chlamydia pneumoniae (C. pneumoniae). Staphylococcus aureus
is a Gram-positive pyogenic coccus and a good inducer of TNF
in mononuclear cells, and it mimics natural conditions (29, 30).
Chlamydia pneumoniae is a Gram-negative bacterium, growing
intracellularly, and it is responsible for different inflammatry
conditions, especially in the lungs and in atherosclerosis.
Chlamydia pneumoniae attach monocytes and multiply in them
(31).The main question was, whether the production of TNF-α,
and TSG-6 could be induced by these criteriae in U-937 cells. It
was demonstrated in a previous study, that C.pneumoniae
upregulated. numerous inflammatory genes in U-937
cells (32).
MATERIALS AND METHODS
Reagents
KYNA (Kynurenic acid) was purchased from Sigma-Aldrich
(Steinheim, Germany). Compounds SZR-72, SZR-73, and SZR-
81 were synthesized by direct amidation of KYNA (33). In
case of SZR-104, SZR-105, and SZR-109, the syntheses were
achieved starting from the corresponding amides followed by
C-3 aminoalkylation with morpholine or with diethylamine in
the presence of formaldehyde (34, 35) (Table 1). KYNA and
the analogs were dissolved in phosphate buffered saline (PBS)
and added in increasing concentration in the µM range to the
cell cultures.
Cell Lines and Infection
U-937 cells were grown in RPMI 1640 medium supplemented
with 10% heat-inactivated FBS (Biowest, Nuaille, France), 2
mmol/L L-glutamine, 1x nonessential amino acids, HEPES 4
mmol/L, 25µg/mL gentamicin, and 0.5µg/mL fungizone. HEp-2
cells were maintained in minimal essential medium (MEM) with
Earle’s salts completed with 10% FBS, 2 mmol/L L-glutamine, 1x
nonessential amino acids, 25µg/mL gentamicin, and 0.5µg/mL
fungizone. All reagents were purchased from SIGMA, St. Louis,
MO, USA, unless otherwise indicated. The cell lines were
purchased from ATCC. For TNF-α and TSG-6 induction, 5
× 105 U-937 cells/mL were infected with 107 heat inactivated
Staphylococcus aureus (S.aureus), or with 5 MOI (multiplicity of
infection) Chlamydia pneumoniae. Cell supernatants were tested
for TNF-α content by ELISA and cell lysates for TSG-6 mRNA by
RT qPCR.
Bacterial Strains
Staphylococcus aureus (S. aureus, SA1) 108 /mL, were heat
inactivated (29) and were used as a TNF-α inducer (30).
Chlamydia pneumoniae (C. pneumoniae)CWL029 strain from
American Types Culture Collection (ATCC) was propagated
in HEp-2 cells. Infective chlamydiae were quantitated by
indirect immunofluorescent method applying anti-Chlamydia
lipopolysaccharide (cLPS) monoclonal antibody (AbD Serotec,
Oxford, United Kingdom) and FITC-labeled anti-mouse IgG
(Sigma-Aldrich, St. Louis, MO). The concentration of infective
elementary bodies (EB)-s was expressed as inclusion forming
units/mL (IFU/mL).
Frontiers in Immunology | www.frontiersin.org 2 June 2019 | Volume 10 | Article 1406
Mándi et al. Kynurenic Acid, TNF and TSG-6
TABLE 1 | KYNA and KYNA analogs used in the experiments.
Code Structure Chemical name Empirical formula and Mw
KYNA 4-hydroxyquinolin-2-carboxylic acid C10H7NO3
189.17
SzR-72 N-(2-(dimethylamino)ethyl)-4-hydroxyquinoline-2-carboxamide hydrochloride C14H18ClN3O2
295.76
SzR-73 N-(3-(dimethylamino)propyl)-4-hydroxyquinoline-2-carboxamide hydrochloride C15H20ClN3O2
309.79
SzR-81 N-(2-(pyrrolidin-1-yl)ethyl)-4-hydroxyquinoline-2-carboxamide hydrochloride C16H20ClN3O2
321.80
SzR-104 N-(2-(dimethylamino)ethyl)-3-(morpholinomethyl)-4-hydroxyquinoline-2-carboxamide C19H26N4O3
358.43
SzR-105 N-(2-(pyrrolidin-1-yl)ethyl)-3-(morpholinomethyl)-4-hydroxyquinoline-2-carboxamide C21H28N4O3
384.47
SzR-109 N-(2-(pyrrolidin-1-yl)ethyl)-3-((diethylamino)methyl)-4-hydroxyquinoline-2-carboxamide C21H30N4O2
370.49
Stimulation of U 937 Cells by Bacteria
Infection
(a) U-937 cells (5 × 105 cells/mL) were stimulated with
107 heat inactivated S. aureus (29) as a TNF inducer (30)
and were incubated for 24 h in CO2 incubator at 37◦C in
complete RPMI. In parallel experiments, the cell cultures were
pretreated for 30min with KYNA and KYNA analoques at
a concentration of 250–500µM. In our prevous experiments
(17), these concentrations proved to be optimal in reducing
cytokine production. Cell supernatants were tested for TNF-α
and TSG-6 content by ELISA and cell lysates for TSG-6 mRNA
by RT qPCR.
(b) U-937 cells were seeded in 24-well plates (5 × 105
cells/well), and the cells were then infected with C. pneumoniae
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at a multiplicity of infection (MOI) of 5 in complete RPMI
with 0.5% glucose and centrifuged at 800 × g for 1 h
RT. The growth medium was replaced in the wells with a
medium containing KYNA analogs at a concentration of 250–
500µM. The culture plates were incubated for 24 h in CO2
incubator at 37◦C. Cell supernatants were tested for TNF-α and
TSG-6 content by ELISA and cell lysates for TSG-6 mRNA
by RT qPCR.
Chlamydial DNA Quantitation
For the quantitative assessment of chlamydial replication, a
direct DNA quantitation method was used (36). The cells
in the 96-well plates were infected with C. pneumoniae at a
multiplicity of infection (MOI) of 5. After 24 and 48 h, the
infected cells in 3 parallel wells were washed in the plates
twice with 200 µL/well phosphate buffered saline (PBS). Then
100 µL Milli-Q water was added to the wells, and the plates
were stored at −80◦C. In order to free the DNA from the
cells, two freeze-thaw cycles were applied. Thoroughly mixed
lysates were used as templates directly for quantitative PCR
(qPCR) using SsoFastTM EvaGreen R© Supermix (BioRad). For the
detection of C. pneumoniae DNA, the following primers were
used: ompA F: 5′ TGCGACGCTATTAGCTTACGT 3′ and ompA
R: 5′ TAGTTTGCAGCAGCGGATCCA 3′. A BLAST search
was performed to check the specificity of the product target
sequence of the primer sets. The primers were synthetized by
Integrated DNA Technologies Inc. (Montreal, Quebec, Canada).
During qPCR reaction, after the 10min at 95◦C polymerase
activation step, 40 PCR cycles of 20 s at 95◦C, and 1min at
64◦C were performed. The fluorescence intensity was measured
at the end of the annealing–extension step. The specificity
of amplification was confirmed by the melting curve analysis.
For each PCR, the cycle threshold (Ct) corresponding to the
cycle, where the amplification curve crossed the base line, was
determined. The difference in Ct values detected in the samples
incubated with KYNA and the analogs at a concentration of
250 and 500µM compared to that of the untreated samples
was calculated.
TNF-α ELISA
The TNF-α concentrations in the supernatants were quantified
by using the TNF-α ELISA kit (Legend Max BioLegend San
Diego) according to the instructions of the manufacturer.
TSG-6 ELISA
The TSG-6 concentrations in the supernatants were quantified by
using the TSG-6 ELISA kit (SIGMA U.S.A. St. Louis) according
to the instructions of the manufacturer.
TSG-6 mRNA Quantification by Reverse
Transcription Quantitative PCR (RT qPCR)
Total RNA was extracted from the samples by using TRI
Reagent (Sigma-Aldrich, St. Louis, MO, USA) according to
the manufacturer’s protocol. The quality and the quantity
of the extracted RNA were assessed by a NanoDrop Lite
spectrophotometer (Thermo Scientific, Waltham, MA, USA).
First-strand cDNA was synthesized by using 2 µg of total RNA
with High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA) strictly adhering to the
manufacturer’s recommendations. The qPCR was conducted
with cDNA, 1 µL of primers (10µM) and SensiFast SYBR R©
No-ROX Mix (Bioline GmbH, Luckenwalde, Germany) in a
total volume of 10 µL. The primers used in the assay were the
following: TSG-6 sense 5′- ACT CAA GTA TGG TCA GCG TAT
TC−3′, TSG-6 antisense 5′- GCC ATG GAC ATC ATC GTA
ACT−3′; β-actin sense 5′- TTC TAC AAT GAG CTG CGT GTG
GCT−3′, and β-actin antisense 5′- TAG CAC AGC CTG GAT
AGC AAC GTA−3′. All primers were synthetized by Integrated
DNA Technologies Inc. (Montreal, Quebec, Canada). The RT-
qPCR was performed in a CFX96 Touch PCR detection system
(Bio-Rad, Hercules, CA, USA). Thermal cycling was initiated
with a denaturation step of 2min at 95 ◦C followed by 40 cycles
each of 10 s at 95◦C and 1min at 60◦C. The fluorescence intensity
was detected at the end of the annealing–extension steps. The
specificity of amplification was confirmed by carrying out a
melting curve analysis. The cycle threshold (Ct) corresponding to
the cycle, where the amplification curve crossed the base line, was
determined. The Ct of target transcripts was compared with that
of β-actin, the difference being referred to as 1Ct. The relative
expression level was given as 2−(11Ct), where 11Ct = 1Ct
for the experimental sample minus 1Ct for the control sample.
Increases in transcripts>2-fold compared to the control samples
were considered to be significant. Uninfected cells were used as
controls. All of the measurements were performed in duplicate
from 3 biological repetitions.
Human Blood Samples
EDTA-anticoagulated peripheral blood samples from 10 healthy
volunteers were obtained.
Samples (1mL each) were incubated in the presence of
heat inactivated S, aureus for 18 hr. Parallel blood samples
were pretreated for 30min with KYNA and KYNA analogs
at a concentration of 500µM. Following the incubation
period, the blood samples were centrifuged at 300 × g, and
the supernatants were tested for TNF-α and TSG-6 content
by ELISA.
For the experiments performed with the human blood we have
the approval of the ethics commitee of the Medical Faculty of the
University. of Szeged (ETT-TUKEB 905/PI/09). This study was
conducted in full accordance with the tenets of Declaration of
Helsinki (1964).
Statistical Analysis
Data are expressed as means ± SD. Differences between
group means were determined by the unpaired Student t-
test. p-values <0.05 were considered significant. Data of
box and whiskers analysis were evaluated by Mann-Whitney
test. The correlation between the TNF-α production and
expression of TSG-6 was evaluated by correlation analysis.
All statistical calculations were performed with the Graph-Pad
Prism 5 statistical program (GraphPad Software Inc., San Diego,
CA, USA).
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FIGURE 1 | KYNA and KYNA analogs attenuate TNF-α levels in SA1
stimulated U-937 cells. U-937 cells (5 × 105/ml) were stimulated with heat
inactivated SA (107/ml) alone, (filled bar), or incubated together with KYNA or
KYNA analogs at a concentration of 500µM, which were added for 30min
prior to the addition of SA1 (open bars). The TNF-α levels in the supernatants
were determined after 24 h by ELISA. Each concentration was tested in
duplicate. Data are shown as means ± SD of three experiments. *p < 0.01;
**p < 0.001 vs. the samples induced only with SA1 determined by the Student
t-test.
RESULTS
KYNA and KYNA Analogs Attenuate TNF-α
Production in U-937 Human Monocytic
Cells Stimulated by Heat Inactivated
Staphylococcus aureus
The maximum TNF-α concentrations in the supernatants in
SA1-induced cultures of U-937 cells without pretreatment of
KYNA and derivates were 95. ± 8.5 pg/mL. At a concentration
of 500µM, all KYNA analogs suppressed the TNF-α level
significantly, except SZR 73 (Figure 1). The new analogs SZR
104, 105, and 109 exerted the most potent inhibitory effects (p
< 0.001) in equimolar (500µM) concentration. Results obtained
with 500µM of the chemicals are demonstrated in Figure 1.
In our previous experiments (17), 25µM KYNA and SZR72
proved to be ineffective. At increasing concentrations (125, 250,
and 500µM), KYNA and SZR72 exhibited increasing inhibitory
effects on TNF-α production. Similar results were obtained in the
present experiments (data not shown), but only the result with
the most effective concentration (500µM) is demonstrated in
this paper (Figure 1).
KYNA and KYNA Analogs Increase TSG-6
mRNA Expression in U-937 Cells
To gain further insight into the connection between the
inhibition of TNF-α production and the induction of TSG-
6 expression exerted by KYNA analoques, we determined
the effects of KYNA analoques on TSG-6 mRNA expression.
Both KYNA and KYNA analogs increased the TSG-6 relative
expression at equimolar concentrations of 500µM (Figure 2)
significantly. SZR 73 was not effective in this respect, similarly
FIGURE 2 | Effect of 500µM of KYNA and KYNA analogs on TSG-6 mRNA
levels in U-937 monocytic cells stimulated with SA1. TSG-6 expressions were
normalized to reference gene of β-actin by using quantitative real-time PCR.
Relative expression was calculated by using the 2−(11Ct) method and is given
as a ratio between the target and the reference gene. Control: TSG-6 mRNA
expression without stimulation, Filled bar: TSG-6 mRNA expression in
SA1-stimulated cells without KYNA or KYNA analoques, open bars: TSG-6
mRNA expression in SA1-stimulated cells in the presence of 500µM KYNA or
KYNA analogs. Data are shown as means ± SD of the results of three
independent experiments. *p < 0.01 vs. SA1 induced cells without chemicals,
**p < 0.001 vs. SA1 induced cells without chemicals, determined by the
Student t-test.
as it was observed in the experiments with TNF-α production.
Thus, we suspect that there is a connection between the
attenuation of SA1-induced TNF protein synthesis and the
TSG-6 gene transcription, which is elevated by KYNA and
KYNA analoques.
KYNA and the KYNA Analogs Differently
Influence TNF-α Production Induced by C.
pneumoniae in U-937 Human
Monocytic Cells
We wanted to compare the effects of KYNA and KYNA
derivates on TNF-α production when the inducer is a Gram-
negative, intracellular bacterium, i.e., Chlamydia pneumoniae (C.
pneumoniae). Our results were unexpected; instead of having
inhibitory effects, KYNA and some of the KYNA analoques
increased the TNF-α production of C. pneumoniae infected U-
937 cells. In contrast, the newly synthetized analogs (SZR104,
SZR 105, and SZR 109) exerted a significant inhibitory effect on
the cytokine synthesis (Figure 3).
KYNA and KYNA Analogs Differently
Influence TSG-6 mRNA Expression in
U-937 Cells Infected With
Chlamydia pneumoniae
C. pneumoniae induced a considerable TSG-6 expression in
U-937 cells. KYNA, SZR72, and SZR81 inhibited the rate
of expression (Figure 4A). Interestingly, the same chemicals
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enhanced the TNF-α production of C. pneumoniae-induced
U-937 cells (Figure 3). On the other hand, further KYNA
analoques (SZR 104, SZR 105, and SZR 109) with different
FIGURE 3 | Effect of KYNA and KYNA analogs on TNF-α production in U-937
human monocytic cells stimulated by Chlamydia pneumonia. U-937 cells were
pretreated for 30min with KYNA or KYNA analogs and thereafter incubated for
24 h with 5 MOI of Chlamydia pneumoniae. U-937 cells (5 × 105/mL) were
infected with 5 MOI of Chlamydia pneumoniae alone (filled bar), or incubated
together with KYNA or KYNA analogs at a concentration of 500µM, which
were added for 30min prior to the addition of the bacteria (open bars). The
TNF-α levels in the supernatants were determined after 24 h. Each
concentration was tested in duplicate. Data are shown as means ± SD of
three experiments. *p < 0.01; **p < 0.001 vs. the samples induced only with
C. pneumoniae determined by the Student t-test.
chemical structure (see Table 1) stimulated TSG-6 expression
(Figure 4B). It is also noteworthy that only these analoques
inhibited significantly the TNF-α production of C. pneumoniae-
induced U-937 cells (Figure 3). Considering the variable effects
of KYNA analogs on the TSG-6 expression and also on the
TNF-α production, we checked the correlation between the two
effects. As it was expected, a significant inverse correlation was
found between the effects on the TNF-α secretion and the TSG-
6 expression exerted by different KYNA analogs (Figure 5).
KYNA, SZR72, and SZR81 induced higher TNF-α secretion by
U-937 cells after C. pneumoniae infection, but they decreased
the TSG-6 expression compared to the cells that were infected
only with C. peumomiae, without any of the compounds (i.e.,
Cpn in Figure 5). In contrast, in the case of the highest rate of
TSG-6 expression (SZR 105), a maximal rate of inhibition of
TNF-α production was observed. Therefore, we suppose that the
different effects of KYNA analoques on the TSG-6 expression in
C. pneumoniae infected cells might explain the difference in their
effects on the secretion of TNF-α.
Altogether, from these data, it seems that inhibition of TNF-
α is not only in correlation with the antiinflammatory effect of
TSG-6, but in this situations, KYNA analogs are able to increase
or even decrease the expression of TSG-6.
Effects of KYNA Analoques on the Quantity
of C. pneumoniae
To ascertain that the effects of KYNA analoques on the TNF-
α or TSG-6 induction is not simply due to their effects on the
replication of C. pneumoniae, we performed experiments for
quantitative assessment of chlamydial replication by a direct
FIGURE 4 | Effect of 500µM of KYNA and KYNA analogs on TSG-6 mRNA levels in U-937 monocytic cells stimulated with Chlamydia pneumoniae at a MOI 5.
TSG-6 expressions were normalized to the reference gene of β-actin by using quantitative real-time PCR. Relative expression was calculated by using the 2−(11Ct)
method and is given as a ratio between the target and the reference gene. Control: TSG-6 mRNA expression without stimulation, Filled bar: TSG-6 mRNA expression
in C. pneumoniae-stimulated cells without KYNA or KYNA analoques, open bars: TSG-6 mRNA expression in C. pneumoniae-stimulated cells in the presence of
500µM KYNA or KYNA analoques. Data are shown as means ± SD of the results of three independent experiments. *p < 0.01 vs. C. pneumoniae- induced cells
without chemicals, **p < 0.001 vs. C. pneumoniae-induced cells without chemicals, determined by the Student t-test. (A) Decreasing, (B) Increasing effects.
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quantitative PCR method (36). C. pneumoniae ompA gene was
detected in the lysate of U-937 cells infected with C. pneumoniae
at a MOI of 5 in the presence or absence of KYNA analoques at
a concentration of 250 or 500µM, respectively. Direct detection
of C. pneumoniae DNA in the lysate of infected cells was done at
24 and 48 h postinfection. There was no significant inhibition or
even elevation in the quantity of chlamydial DNA in the presence
of different KYNA analoques after the 24 h (open bars) or 48 h
(filled bars) incubation period. The results of the samples tested
at 24 and 48 h of incubation are presented in Figure 6. Therefore,
FIGURE 5 | Correlation between the TSG-6 expression and TNF-α production
by U-937 cells infected with C. pneumoniae at a MOI 5 in the presence of
KYNA or the analogs. U-937 cells were pretreated for 30min with KYNA or
KYNA analogs at a concentration of 500µM, and thereafter incubated for 24 h
with 5 MOI of Chlamydia pneumoniae. The TNF-α levels in the supernatants
were determined with ELISA assay, and the TSG-6 expression by RT qPCR
reactions. The significance of correlation was calculated by correlation analysis
with the Graph-Pad Prism 5 statistical program. Symbols and numbers
represent the data obtained with KYNA or KYNA analogs. Cpn: incubation
only with Chlamydia pneumoniae without compounds. The correlation
coefficient, r value is-0.891, the p-value = 0.0072, the 95% confidence interval
is −0.9838 to −0,4174.
we assume that KYNA analoques do not influence the replication
or the quantity of C. pneumoniae.
Effects of KYNA Analogs on TGS-6 Protein
Production in U-937 Human Monocytic
Cells Stimulated With Heat Inactivated S.
aureus or by Chlamydia pneumoniae
To ascertain whether the effects of KYNA and analogs on
the TSG-6 expression influence parallelly the protein level,
the TSG-6 concentrations in the supernatants of U-937 cells
were determined.
At a concentration of 500µM, KYNA and KYNA analogs
increased the TGF-6 level significantly, except SZR 73 in SA1
induced cells (Figure 7A). The new analogs SZR 104, 105, and
109 exerted the most potent stimulatory effects (p < 0.001) in
equimolar (500µM) concentration. C. pneumoniae induced also
TSG-6 production in U-937 cells, but KYNA, SZR72, and SZR81
decreased the level of TSG-6 protein expression (Figure 7B).
On the other hand, further KYNA analoques (SZR 104, SZR
105, and SZR 109) increased the TSG-6 concentration in the
supernatants (7b). These experiments obtained with 500µM of
KYNA and KYNA analogs support the results obtained with
RT PCR data demonstrating the effects of the chemicals on the
TSG-6 RNA expression.
KYNA Analogs SZR 72 and SZR 105
Attenuate TNF-α Production and Increase
TSG-6 Secretion in Human Whole Blood
Cells Stimulated by Heat Inactivated
Staphylococcus aureus
Some of the results obtained by in vitro experiments with U-
937 monocytic cells were repeated by “ex vivo” experimets
FIGURE 6 | Analysis of the effect of kynurenic acid derivates on C. pneumoniae growth in U-937 cells based on quantitation of chlamydial DNA by qPCR. The cells
were infected in 96-well plates at a MOI of 5 in a medium containing kinurenic acid derivates. Direct detection of C. pneumoniae ompA gene in the lysate of infected
cells was performed at 24 (open bars) and 48 h (filled bars) postinfection. Fold change in the quantity of chlamydial DNA in kinurenic acid derivate treated cultures
compared to the quantities detected in non-treated cultures was calculated. The mean of fold change in 3 parallel cultures and SD are shown. The differences are not
significant.
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FIGURE 7 | Effect of KYNA and KYNA analogs on TGS-6 protein production
in U-937 human monocytic cells stimulated with heat inactivated S. aureus
(SA1) (A) or by Chlamydia pneumoniae (B). (A) U-937 cells (5 × 105/ml) were
stimulated with heat inactivated SA1 (107/ml) alone, (filled bar), or incubated
together with KYNA or KYNA analogs at a concentration of 500µM, which
were added for 30min prior to the addition of SA1 (open bars). The TSG-6
levels in the supernatants were determined after 24 h by ELISA. Each
concentration was tested in duplicate. Data are shown as means ± SD of
three experiments. *p < 0.01; **p < 0.001 vs. the samples induced only with
SA1 determined by the Student t-test. (B) U-937 cells were pretreated for
30min with KYNA or KYNA analogs and thereafter incubated for 24 h with 5
MOI of Chlamydia pneumoniae. U-937 cells (5 × 105/mL) were infected with 5
MOI of Chlamydia pneumoniae alone (filled bar), or incubated together with
KYNA or KYNA analogs at a concentration of 500µM, which were added for
30min prior to the addition of the bacteria (open bars). The TSG-6 levels in the
supernatants were determined after 24 h. Each concentration was tested in
duplicate. Data are shown as means ±SD of three experiments. *p < 0.01; **p
< 0.001 vs. the samples induced only with C. pneumoniae determined by the
Student t-test.
investigating the effects of two KYNA analogs in human
peripheral blood.
There was big individual differences in the TNF-α
concentrations and in TSG-6 concentrations in the supernatants
in SA1-induced blood cultures (Figure 8), between 179 pg/ml
and 850 pg/ml, and between 150 and 750 pg/ml, respectively.
At a concentration of 500µM, both SZR 72 and SZR 105
suppressed the TNF-α level significantly in the S. aureus
induced blood cultures. Again, the new analog SZR 105
exerted more potent inhibitory effect (p = 0.001) in equimolar
(500µM) concentration. Similarly to the effects on U-937
cells, the KYNA analogs SZR72 and SZR 105 significantly
FIGURE 8 | Effect of KYNA analogs SZR 72 and SZR 105 on the TNF-α
production and TSG-6 secretion in human whole blood cells stimulated by
heat inactivated Staphylococcus aureus. EDTA-anticoagulated blood samples
1–1mL each of 10 donors were incubated with SZR72 or SZR105 at a
concentration of 500µM for 30min prior to the addition of heat inactivated
Staphylococcus aureus (10 7/ml) The concentrations of TNF-α and that of
TSG-6 in the plasma were determined after 18 h incubation period by TNF-α
and TSG-6 ELISA plotted on the left and right Y axis, respectively. The data are
depicted as box and whiskers plots, where the lines inside the boxes denote
medians, and the boxes mark the interval between 25 and 75 percentile, and
the whiskers the maximum and minimum. Significance were determined by
the Mann-Whitney test.
increased the TSG-6 concentrations in SA1 induced blood
samples (Figure 8).
DISCUSSION
In our experiments, KYNA and different KYNA derivates
inhibited the TNF-α production of U-937 cells stimulated
with heat inactivated Staphylococcus aureus. The rate of the
inhibition was variable according the structure of the analoques
(Figure 1). The effect of the analogs were compared in equimolar
concentration on the TNF-α production when the inducer
was Chlamydia pneumoniae, a Gram negative, intracellular
bacterium. In these experiments, however, not all KYNA
derivates inhibited TNF-α production by U-937 monocytic cells;
moreover, KYNA itself, and SZR72 and SZR81 increased it
(Figure 3). We hypothesized that the difference in the influence
on the TNF-α production might be connected with the difference
in the TSG-6 expression (Figure 4).
The production of TNF-α in C. pneumoniae infected cells
was inhibited only by the KYNA derivates (SZR 104, SZR105,
SZR109) that upregulated the expression of TSG-6 (Figures 4, 5).
It is noteworthy, that TSG-6 itself does not only exert an
antiinflammatory effect (20, 26, 27), but its expression might be
under the influence of KYNA (37). It has been published that
kynurenic acid controls TSG-6-mediated immunosuppression
of the human mesenchymal stem cells (MSCs). In elegant
experiments, it has been demonstrated that KYNA specifically
regulates TSG-6 production by activating aryl hydrocarbon
receptor (AHR). KYNA activates AHR, which directly
binds to the TSG-6 promoter to enhance TSG-6 expression.
Moreover, KYNA-pretreated MSCs can further boost TSG-6
production, and thus enhance the therapeutic capacity of human
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MSCs against lipopolysaccharide (LPS)-induced acute lung
injury (37).
We found that in most experiments, TSG-6 expression was
up-regulated in U-937 monocytic cells stimulated with bacterial
components, and KYNA and KYNA analogs were able to
influence the rate of expression of TSG-6. The elevation of
the TSG-6 expression might be one of the mechanisms that
are responsible for the suppression of TNF-α production as
a feedback effect. This effect was clearly demonstrated in our
experiments using heat inactivated S. aureus as a cytokine
inducer. In the case of C. pneumoniae infection, however, KYNA
and KYNA analoques did not exert this effect uniformly. Some of
them increased TSG-6 expression with a concomitant inhibition
of the production of TNF-α, but several compounds (KYNA,
SZR72, and SZR 81) rather decreased the expression of TSG-6,
and it is very likely that this could lead to an elevated TNF-α
production compared to the TNF-α production of U-937 cells
infected with C. pneumoniae without any KYNA analoque. We
hypothesized that the explanation of the difference in the results
might be due to the different chemical structure of the analoques
(see Table 1). The examined substrates (SZR-72, SZR-73 SZR-
81, SZR-104, SZR-105, and SZR-109) can be classified into two
classes of compounds: the first are amide derivatives (SZR-72,
SZR-73, SZR-81) containing cationic center at the amide side
chain. The second class of compounds (SZR-104, SZR-105, and
SZR-109) are the C-3 aminoalkylated amides, therefore they can
be interpreted as derivatives with dual cationic centers.
They could differently influence the binding of C. pneumoniae
to the Toll-like receptor 2 (TLR2), and especially, differently
activate AHR in the presence of C. pneumoniae. It has to be
highlighted that the newly synthetized analogs, SZR 105 and SZR
109, were the most potent inducers of TSG-6 expression, and the
highest inhibitors of TNF-α production in both types of bacterial
inducers. The study of the exact effect of Chlamydia pneumoniae
on the interaction between AHR and some KYNA analogs needs
to be further investigated and proved.
Whatever the explanation is, our results indicate that there
is a close connection between TNF production and TSG-6
expression, and there is an inverse correlation between the TSG-6
expression and TNF-α production in the presence of KYNA and
KYNA analogs.
This negative correlation was further demonstrated at
the protein level of TSG-6 measured in the supernatants
of U-937 cells. and also in unseparated human peripheral
blood samples
The stimulation of TSG-6 expression by KYNA and KYNA
derivates might be one of the mechanisms that have an important
role in their suppressive effect on TNF-α production. TSG-6
expression following activation with bacterial components could
participate in the suppression of inflammatory cytokines, such as
TNF-α, and it is noteworthy that KYNA and especially KYNA
analogs are able to enhance this effect. Further studies are
required to elucidate the different effects of KYNA derivates in
the case of different bacterial inducers and the possible benefits
of targeting TSG-6 expression by kynurenines in inflammatory
conditions following infections.
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